

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
6 April 2006 (06.04.2006)

PCT

(10) International Publication Number  
WO 2006/035203 A1

(51) International Patent Classification:

A61K 31/506 (2006.01) A61P 35/00 (2006.01)  
A61K 31/517 (2006.01) A61P 35/02 (2006.01)

Robert [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(21) International Application Number:

PCT/GB2005/003672

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; AstraZeneca AB, S-SE-151 85 Södertälje (SE).

(22) International Filing Date:

23 September 2005 (23.09.2005)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0421436.7 27 September 2004 (27.09.2004) GB  
0506725.1 1 April 2005 (01.04.2005) GB

(71) Applicant (for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MC, MD, MK, ML, MN, MR, MW, MX, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG only): **ASTRAZENECA AB** [SE/SE]; S-SE-151 85 Södertälje (SE).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

Published:

— with international search report

(72) Inventor; and

(75) Inventor/Applicant (for US only): **WEDGE, Stephen,**

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CANCER COMBINATION THERAPY COMPRISING AZD2171 AND IMATINIB

(57) Abstract: The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumor or a leukaemia, which comprises the administration of AZD2171 in combination with imatinib; to a pharmaceutical composition comprising AZD2171 and imatinib; to a combination product comprising AZD2171 and imatinib for use in a method of treatment of a human or animal body by therapy; to a kit comprising AZD2171 and imatinib; to the use of AZD2171 and imatinib in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionizing radiation.

WO 2006/035203 A1

The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour or a leukaemia, which comprises the administration of AZD2171 in combination with imatinib; to a pharmaceutical composition comprising AZD2171 and imatinib; to a combination product comprising AZD2171 and imatinib for use in a method of treatment of a human or animal body by therapy; to a kit comprising AZD2171 and imatinib; to the use of AZD2171 and imatinib in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation.

Normal angiogenesis plays an important role in a variety of processes including embryonic development, wound healing and several components of female reproductive function. Undesirable or pathological angiogenesis has been associated with disease states including diabetic retinopathy, psoriasis, cancer, rheumatoid arthritis, atheroma, Kaposi's sarcoma and haemangioma (Fan et al, 1995, Trends Pharmacol. Sci. 16: 57-66; Folkman, 1995, Nature Medicine 1: 27-31). Alteration of vascular permeability is thought to play a role in both normal and pathological physiological processes (Cullinan-Bove et al, 1993, Endocrinology 133: 829-837; Senger et al, 1993, Cancer and Metastasis Reviews, 12: 303-324). Several polypeptides with *in vitro* endothelial cell growth promoting activity have been identified including, acidic and basic fibroblast growth factors (aFGF & bFGF) and vascular endothelial growth factor (VEGF). By virtue of the restricted expression of its receptors, the growth factor activity of VEGF, in contrast to that of the FGFs, is relatively specific towards endothelial cells. Recent evidence indicates that VEGF is an important stimulator of both normal and pathological angiogenesis (Jakeman et al, 1993, Endocrinology, 133: 848-859; Kolch et al, 1995, Breast Cancer Research and Treatment, 36:139-155) and vascular permeability (Connolly et al, 1989, J. Biol. Chem. 264: 20017-20024). Antagonism of VEGF action by sequestration of VEGF with antibody can result in inhibition of tumour growth (Kim et al, 1993, Nature 362: 841-844).

Receptor tyrosine kinases (RTKs) are important in the transmission of biochemical signals across the plasma membrane of cells. These transmembrane molecules


characteristically consist of an extracellular ligand-binding domain connected through a segment in the plasma membrane to an intracellular tyrosine kinase domain. Binding of ligand to the receptor results in stimulation of the receptor-associated tyrosine kinase activity which leads to phosphorylation of tyrosine residues on both the receptor and other  
5 intracellular molecules. These changes in tyrosine phosphorylation initiate a signalling cascade leading to a variety of cellular responses. To date, at least nineteen distinct RTK subfamilies, defined by amino acid sequence homology, have been identified. One of these subfamilies is presently comprised by the fms-like tyrosine kinase receptor, Flt-1 (also referred to as VEGFR-1), the kinase insert domain-containing receptor, KDR (also referred  
10 to as VEGFR-2 or Flk-1), and another fms-like tyrosine kinase receptor, Flt-4. Two of these related RTKs, Flt-1 and KDR, have been shown to bind VEGF with high affinity (De Vries et al, 1992, *Science* 255: 989-991; Terman et al, 1992, *Biochem. Biophys. Res. Comm.* 1992, 187: 1579-1586). Binding of VEGF to these receptors expressed in heterologous cells has been associated with changes in the tyrosine phosphorylation status of cellular proteins  
15 and calcium fluxes.

VEGF is a key stimulus for vasculogenesis and angiogenesis. This cytokine induces a vascular sprouting phenotype by inducing endothelial cell proliferation, protease expression and migration, and subsequent organisation of cells to form a capillary tube (Keck, P.J., Hauser, S.D., Krivi, G., Sanzo, K., Warren, T., Feder, J., and Connolly, D.T.,  
20 *Science* (Washington DC), 246: 1309-1312, 1989; Lamoreaux, W.J., Fitzgerald, M.E., Reiner, A., Hasty, K.A., and Charles, S.T., *Microvasc. Res.*, 55: 29-42, 1998; Pepper, M.S., Montesano, R., Mandroita, S.J., Orci, L. and Vassalli, J.D., *Enzyme Protein*, 49: 138-162, 1996.). In addition, VEGF induces significant vascular permeability (Dvorak, H.F., Detmar, M., Claffey, K.P., Nagy, J.A., van de Water, L., and Senger, D.R., (*Int. Arch.*  
25 *Allergy Immunol.*, 107: 233-235, 1995; Bates, D.O., Heald, R.I., Curry, F.E. and Williams, B. *J. Physiol. (Lond.)*, 533: 263-272, 2001), promoting formation of a hyper-permeable, immature vascular network which is characteristic of pathological angiogenesis.

It has been shown that activation of KDR alone is sufficient to promote all of the major phenotypic responses to VEGF, including endothelial cell proliferation, migration,  
30 and survival, and the induction of vascular permeability (Meyer, M., Clauss, M., Lepplé-Wienhues, A., Waltenberger, J., Augustin, H.G., Ziche, M., Lanz, C., Büttner, M., Rziha, H.-J., and Dehio, C., *EMBO J.*, 18: 363-374, 1999; Zeng, H., Sanyal, S. and Mukhopadhyay,

D., J. Biol. Chem., 276: 32714-32719, 2001; Gille, H., Kowalski, J., Li, B., LeCouter, J., Moffat, B, Zioncheck, T.F., Pelletier, N. and Ferrara, N., J. Biol. Chem., 276: 3222-3230, 2001).

Quinazoline derivatives which are inhibitors of VEGF receptor tyrosine kinase are described in International Patent Application Publication No. WO 00/47212. AZD2171 is described in WO 00/47212 and is Example 240 therein. AZD2171 is 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline:



10

AZD2171

AZD2171 shows excellent activity in the *in vitro* (a) enzyme and (b) HUVEC assays that are described in WO 00/47212 (pages 80-83). The AZD2171 IC<sub>50</sub> values for inhibition of isolated KDR (VEGFR-2) and Flt-1 (VEGFR-1) tyrosine kinase activities in the enzyme assay were <1 nM and 5 ± 2 nM respectively. AZD2171 inhibits VEGF-stimulated endothelial cell proliferation potently (IC<sub>50</sub> value of 0.4 ± 0.2 nM in the HUVEC assay), but does not inhibit basal endothelial cell proliferation appreciably at a > 1250 fold greater concentration (IC<sub>50</sub> value is > 500 nM). The growth of a Calu-6 tumour xenograft in the *in vivo* solid tumour model described in WO 00/47212 (page 83) was inhibited by 49%<sup>\*\*</sup>, 69%<sup>\*\*\*</sup> and 91%<sup>\*\*\*</sup> following 28 days of once-daily oral treatment with 1.5, 3 and 6 mg/kg/day AZD2171 respectively (P<sup>\*\*</sup> < 0.01, P<sup>\*\*\*</sup> < 0.0001; one-tailed t test). AZD2171 has been shown to elicit broad-spectrum anti-tumour activity in a range of models following once-daily oral administration.

In WO 00/47212 it is stated that compounds of the invention:  
“may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be

25

achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment.”

WO 00/47212 then goes on to describe examples of such conjoint treatment including surgery, radiotherapy and various types of chemotherapeutic agent including  
5 “inhibitors of growth factor function, (such growth factors include for example platelet derived growth factor and hepatocyte growth factor such inhibitors include growth factor antibodies, growth factor receptor antibodies, tyrosine kinase inhibitors and serine/threonine kinase inhibitors)”.

Nowhere in WO 00/47212 is the specific combination of AZD2171 and imatinib  
10 suggested.

Nowhere in WO 00/47212 does it state that use of any compound of the invention therein with other treatments will produce surprisingly beneficial effects.

We have now found that AZD2171, as well as producing an antiangiogenic and/or vascular permeability reducing effect by virtue of inhibiting KDR, can have an additional  
15 direct antiproliferative effect on tumour cells mediated by inhibition of stem cell factor receptor tyrosine kinase (SCF RTK, commonly known as c-kit). We have found that AZD2171 inhibits c-kit and it is expected that AZD2171 will inhibit mutated and wild-type c-kit. c-Kit and its ligand SCF have been found in numerous solid and haematological malignancies, including gastrointestinal stromal tumours, primary brain tumours such as  
20 glioblastoma, glioma and medulloblastoma, small cell lung cancer (SCLC), malignant mesothelioma, tumours of the testis such as seminoma and testicular teratocarcinoma, tumours of the ovary such as dysgerminoma and gonadoblastoma, chronic myelogenous leukaemia (CML), acute myelogenous leukaemia (AML) and mastocytosis (see for example *Jnl. Clin. Oncol.*, 2004, 22, 4514-4522). c-Kit has also been found in  
25 hepatocellular carcinoma, (*Am J Clin Pathol.* 2005 Jul;124(1):31-6), and colorectal carcinoma, (*Case Reports Tumour Biol.* 1993;14(5):295-302). c-Kit is an important signal transduction inhibitor in certain cancers such as gastrointestinal tumours (GIST), (Bümming et al, 2003 *Br J Cancer* 89, 460-464), small cell lung cancer (SCLC), (Pott et al., 2003, *Annals of Oncology* 14: 894-879), and chronic myelogenous leukaemia (CML),  
30 (Goselink et al.1992, *Blood* 80, 750-757 and Muroi et al, 1995, *Leuk Lymphoma* 16, 297-305). c-Kit is also an important signal transduction inhibitor in soft tissue sarcomas like leiomyosarcoma. We have found that AZD2171 inhibits PDGFR $\beta$  phosphorylation in

murine NIH3T3 fibroblasts but at a greater than 30-fold concentration of that required to achieve an inhibition comparable with that observed versus KDR (Ogilvie et al, Proc Am Assoc Cancer Res 2004;45:1051). In comparison to inhibition of KDR phosphorylation in HUVEC, 10 and 16 fold higher concentrations of AZD2171 were required for comparable inhibition of PDGFR- $\alpha$  and - $\beta$  phosphorylation respectively in MG63 osteosarcoma cells. The effect of AZD2171 on PDGFR- $\alpha$  dependent cellular proliferation (stimulated by PDGF-AA) was examined in MG63 cells and an IC<sub>50</sub> value of 0.04  $\mu$ M determined. This concentration is 100 fold greater than that required for comparable inhibition of VEGF-induced proliferation in HUVEC, (Wedge et al, Cancer Res. 2005; 65:(10)).

Imatinib (also known as Glivec® or Gleevec®) is a protein tyrosine kinase inhibitor that inhibits Bcr-Abl tyrosine kinase. Imatinib also inhibits platelet derived growth factor receptor tyrosine kinase (PDGF RTK) and stem cell factor receptor tyrosine kinase (SCF RTK, c-kit). It is known that imatinib only targets mutated c-kit. Imatinib has been used, in particular, in the treatment of chronic myelogenous leukaemia (CML) and in the treatment of gastrointestinal stromal tumours (GIST).

Imatinib may also be effective in myeloproliferative disorders for example chronic eosinophilic leukaemia, hypereosinophilic syndrome and polycythaemia rubra vera (Apperley JF et al New Engl J Med. 2002;347:481-487 and Silver RT et al Blood, 2004;104:11. Abstract 656) and also in myelodysplastic syndrome for example chronic myelomonocytic leukaemia (CMML) and myelofibrosis with myeloid metaplasia (Blood. 2004 Oct 1;104(7):1931-9. Epub 2004 May 27).

Unexpectedly and surprisingly we have now found that the particular compound AZD2171 used in combination with a particular selection from the combination therapies listed in WO 00/47212, namely with imatinib, produces significantly better effects than any one of AZD2171 and imatinib used alone. In particular, AZD2171 used in combination with imatinib produces significantly better effects on solid tumours than any one of AZD2171 and imatinib used alone.

Anti-cancer effects of a method of treatment of the present invention include, but are not limited to, anti-tumour effects, the response rate, the time to disease progression and the survival rate. Anti-tumour effects of a method of treatment of the present invention include but are not limited to, inhibition of tumour growth, tumour growth delay, regression of tumour, shrinkage of tumour, increased time to regrowth of tumour on

cessation of treatment, slowing of disease progression. It is expected that when a method of treatment of the present invention is administered to a warm-blooded animal such as a human, in need of treatment for cancer, said method of treatment will produce an effect, as measured by, for example, one or more of: the extent of the anti-tumour effect, the  
5 response rate, the time to disease progression and the survival rate. Anti-cancer effects include prophylactic treatment as well as treatment of existing disease.

According to the present invention there is provided a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of  
10 AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib.

According to a further aspect of the present invention there is provided a method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically  
15 acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib.

According to a further aspect of the present invention there is provided a method for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or  
20 a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib.

According to a further aspect of the present invention there is provided a method for the treatment of a gastrointestinal stromal tumour (GIST) in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of  
25 AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib.

According to a further aspect of the present invention there is provided a method for the treatment of a leukaemia in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a  
30 pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib.

According to a further aspect of the present invention there is provided a method for the treatment of chronic myelogenous leukaemia (CML) in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib.

According to a further aspect of the present invention there is provided a method for the treatment of small cell lung cancer (SCLC) in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib.

According to a further aspect of the present invention there is provided a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib; wherein AZD2171 and imatinib may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.

According to a further aspect of the present invention there is provided a method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib; wherein AZD2171 and imatinib may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.

According to a further aspect of the present invention there is provided a method for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib; wherein AZD2171 and imatinib may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.

According to a further aspect of the present invention there is provided a method for the treatment of a gastrointestinal stromal tumour (GIST) in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of

AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib; wherein AZD2171 and imatinib may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.

5 According to a further aspect of the present invention there is provided a method for the treatment of a leukaemia in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib; wherein AZD2171 and imatinib may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.

10 According to a further aspect of the present invention there is provided a method for the treatment of chronic myelogenous leukaemia (CML) in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib; wherein AZD2171 and imatinib may each optionally  
15 be administered together with a pharmaceutically acceptable excipient or carrier.

According to a further aspect of the present invention there is provided a method for the treatment of small cell lung cancer (SCLC) in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective  
20 amount of imatinib; wherein AZD2171 and imatinib may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises AZD2171 or a pharmaceutically acceptable salt thereof, and imatinib in association with a pharmaceutically acceptable excipient or carrier.

25 According to a further aspect of the present invention there is provided a combination product comprising AZD2171 or a pharmaceutically acceptable salt thereof and imatinib, for use in a method of treatment of a human or animal body by therapy.

According to a further aspect of the present invention there is provided a kit comprising AZD2171 or a pharmaceutically acceptable salt thereof, and imatinib.

30 According to a further aspect of the present invention there is provided a kit comprising:

a) AZD2171 or a pharmaceutically acceptable salt thereof in a first unit dosage form;

- b) imatinib in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

According to a further aspect of the present invention there is provided a kit comprising:

- 5 a) AZD2171 or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable excipient or carrier, in a first unit dosage form;
- b) imatinib together with a pharmaceutically acceptable excipient or carrier, in a second unit dosage form; and
- c) container means for containing said first and second dosage forms.

10 According to a further aspect of the present invention there is provided the use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human.

15 According to a further aspect of the present invention there is provided the use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human.

20 According to a further aspect of the present invention there is provided the use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of a medicament for use in the production of an anti-tumour effect in a warm-blooded animal such as a human.

25 According to a further aspect of the present invention there is provided the use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of a medicament for use in the production of an anti-tumour effect in a warm-blooded animal such as a human wherein the tumour is a gastrointestinal stromal tumour (GIST).

According to a further aspect of the present invention there is provided the use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human wherein the cancer is a leukaemia.

30 According to a further aspect of the present invention there is provided the use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of

a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human wherein the cancer is chronic myelogenous leukaemia (CML).

According to a further aspect of the present invention there is provided the use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of  
5 a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human wherein the cancer is small cell lung cancer (SCLC).

According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, optionally together with a pharmaceutically  
10 acceptable excipient or carrier, and the simultaneous, sequential or separate administration of an effective amount of imatinib; wherein imatinib may optionally be administered together with a pharmaceutically acceptable excipient or carrier; to a warm-blooded animal such as a human in need of such therapeutic treatment.

Such therapeutic treatment includes an antiangiogenic and/or vascular permeability effect,  
15 an anti-cancer effect and an anti-tumour effect.

A combination treatment of the present invention as defined herein may be achieved by way of the simultaneous, sequential or separate administration of the individual components of said treatment. A combination treatment as defined herein may be applied as a sole therapy or may involve surgery or radiotherapy or an additional  
20 chemotherapeutic agent in addition to a combination treatment of the invention. Surgery may comprise the step of partial or complete tumour resection, prior to, during or after the administration of the combination treatment with AZD2171 described herein.

Other chemotherapeutic agents for optional use with a combination treatment of the present invention include those described in WO 00/47212 which is incorporated herein by  
25 reference. Such chemotherapy may cover five main categories of therapeutic agent:

- (i) other antiangiogenic agents including vascular targeting agents;
- (ii) cytostatic agents;
- (iii) biological response modifiers (for example interferon);
- (iv) antibodies (for example edrecolomab); and
- 30 (v) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology; and other categories of agent are:
  - (vi) antisense therapies;

- (vii) gene therapy approaches; and
- (ix) immunotherapy approaches.

Particular examples of chemotherapeutic agents for use with a combination treatment of the present invention are raltitrexed, etoposide, vinorelbine, paclitaxel, docetaxel, cisplatin, oxaliplatin, carboplatin, gemcitabine, irinotecan (CPT-11), 5-fluorouracil (5-FU, (including capecitabine)) and hydroxyurea. Such combinations are expected to be particularly useful for the treatment of cancer of the lung, head and neck, brain, colon, rectum, oesophagus, stomach, cervix, ovary, skin, breast, bladder, prostate, pancreas, liver and including haematological malignancies. Such combinations are expected to be more particularly useful for the treatment of gastrointestinal stromal tumours (GIST), small cell lung cancer (SCLC), glioblastoma multiforme (GBM), malignant glioma, malignant mesothelioma, mastocytosis and leukaemias such as acute myelogenous leukaemia (AML) and chronic myelogenous leukaemia (CML). Such combinations are expected to be especially useful for the treatment of gastrointestinal stromal tumours (GIST), small cell lung cancer (SCLC), and leukaemias such as chronic myelogenous leukaemia (CML). Such combinations are also expected to be particularly useful for the treatment of hepatocellular carcinoma (HCC). Such combinations are also expected to be particularly useful for the treatment of soft tissue sarcomas. Such combinations are also expected to be particularly useful for the treatment of myeloproliferative disorders and myelodysplastic syndrome.

The administration of a triple combination of AZD2171, imatinib and ionising radiation may produce effects, such as anti-tumour effects, greater than those achieved with any of AZD2171, imatinib and ionising radiation used alone, greater than those achieved with the combination of AZD2171 and imatinib, greater than those achieved with the combination of AZD2171 and ionising radiation, greater than those achieved with the combination of imatinib and ionising radiation.

According to the present invention there is provided a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib and before, after or simultaneously with an effective amount of ionising radiation.

According to a further aspect of the present invention there is provided a method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib  
5 and before, after or simultaneously with an effective amount of ionising radiation.

According to a further aspect of the present invention there is provided a method for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective  
10 amount of imatinib and before, after or simultaneously with an effective amount of ionising radiation.

According to a further aspect of the present invention there is provided a method for the treatment of a gastrointestinal stromal tumour (GIST) in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of  
15 AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib and before, after or simultaneously with an effective amount of ionising radiation.

According to a further aspect of the present invention there is provided a method for the treatment of a leukaemia in a warm-blooded animal such as a human, which  
20 comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib and before, after or simultaneously with an effective amount of ionising radiation.

According to a further aspect of the present invention there is provided a method  
25 for the treatment of chronic myelogenous leukaemia (CML) in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib and before, after or simultaneously with an effective amount of ionising radiation.

30 According to a further aspect of the present invention there is provided a method for the treatment of small cell lung cancer (SCLC) in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or

a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib and before, after or simultaneously with an effective amount of ionising radiation.

According to a further aspect of the present invention there is provided a method  
5 for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib and before, after or simultaneously with an effective amount of ionising radiation, wherein AZD2171 and imatinib may each  
10 optionally be administered together with a pharmaceutically acceptable excipient or carrier.

According to a further aspect of the present invention there is provided a method for the treatment of a cancer in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically  
15 acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib and before, after or simultaneously with an effective amount of ionising radiation, wherein AZD2171 and imatinib may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.

According to a further aspect of the present invention there is provided a method  
20 for the treatment of a cancer involving a solid tumour in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib and before, after or simultaneously with an effective amount of ionising radiation, wherein AZD2171 and imatinib may each optionally be administered  
25 together with a pharmaceutically acceptable excipient or carrier.

According to a further aspect of the present invention there is provided a method for the treatment of a gastrointestinal stromal tumour (GIST) in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously  
30 with an effective amount of imatinib and before, after or simultaneously with an effective amount of ionising radiation, wherein AZD2171 and imatinib may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.

According to a further aspect of the present invention there is provided a method for the treatment of a leukaemia in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib and before, after or simultaneously with an effective amount of ionising radiation, wherein AZD2171 and imatinib may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.

According to a further aspect of the present invention there is provided a method for the treatment of chronic myelogenous leukaemia (CML) in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib and before, after or simultaneously with an effective amount of ionising radiation, wherein AZD2171 and imatinib may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.

According to a further aspect of the present invention there is provided a method for the treatment of small cell lung cancer (SCLC) in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib and before, after or simultaneously with an effective amount of ionising radiation, wherein AZD2171 and imatinib may each optionally be administered together with a pharmaceutically acceptable excipient or carrier.

According to a further aspect of the present invention there is provided the use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is being treated with ionising radiation.

According to a further aspect of the present invention there is provided the use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human which is being treated with ionising radiation.

According to a further aspect of the present invention there is provided the use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of

a medicament for use in the production of an anti-tumour effect in a warm-blooded animal such as a human which is being treated with ionising radiation.

According to a further aspect of the present invention there is provided the use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of  
5 a medicament for use in the production of an anti-tumour effect in a warm-blooded animal such as a human which is being treated with ionising radiation wherein the tumour is a gastrointestinal stromal tumour (GIST).

According to a further aspect of the present invention there is provided the use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of  
10 a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human which is being treated with ionising radiation wherein the cancer is a leukaemia.

According to a further aspect of the present invention there is provided the use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of  
15 a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human which is being treated with ionising radiation wherein the cancer is chronic myelogenous leukaemia (CML).

According to a further aspect of the present invention there is provided the use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of  
20 a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human which is being treated with ionising radiation wherein the cancer is small cell lung cancer (SCLC).

According to a further aspect of the present invention there is provided a therapeutic combination treatment comprising the administration of an effective amount of  
25 AZD2171 or a pharmaceutically acceptable salt thereof, optionally together with a pharmaceutically acceptable excipient or carrier, and the administration of an effective amount of imatinib, optionally together with a pharmaceutically acceptable excipient or carrier and the administration of an effective amount of ionising radiation, to a warm-blooded animal such as a human in need of such therapeutic treatment wherein the  
30 AZD2171, imatinib and ionising radiation may be administered simultaneously, sequentially or separately and in any order.

A warm-blooded animal such as a human which is being treated with ionising radiation means a warm-blooded animal such as a human which is treated with ionising radiation before, after or at the same time as the administration of a medicament or combination treatment comprising AZD2171 and imatinib. For example said ionising  
5 radiation may be given to said warm-blooded animal such as a human within the period of a week before to a week after the administration of a medicament or combination treatment comprising AZD2171 and imatinib. This means that AZD2171, imatinib and ionising radiation may be administered separately or sequentially in any order, or may be administered simultaneously. The warm-blooded animal may experience the effect of each  
10 of AZD2171, imatinib and radiation simultaneously.

According to one aspect of the present invention the ionising radiation is administered before one of AZD2171 and imatinib or after one of AZD2171 and imatinib.

According to one aspect of the present invention the ionising radiation is administered before both AZD2171 and imatinib or after both AZD2171 and imatinib.

15 According to one aspect of the present invention AZD2171 is administered to a warm-blooded animal after the animal has been treated with ionising radiation.

According to another aspect of the present invention the effect of a method of treatment of the present invention is expected to be at least equivalent to the addition of the effects of each of the components of said treatment used alone, that is, of each of  
20 AZD2171 and imatinib used alone or of each of AZD2171, imatinib and ionising radiation used alone.

According to another aspect of the present invention the effect of a method of treatment of the present invention is expected to be greater than the addition of the effects of each of the components of said treatment used alone, that is, of each of AZD2171 and  
25 imatinib used alone or of each of AZD2171, imatinib and ionising radiation used alone.

According to another aspect of the present invention the effect of a method of treatment of the present invention is expected to be a synergistic effect.

According to the present invention a combination treatment is defined as affording a synergistic effect if the effect is therapeutically superior, as measured by, for example,  
30 the extent of the response, the response rate, the time to disease progression or the survival period, to that achievable on dosing one or other of the components of the combination treatment at its conventional dose. For example, the effect of the combination treatment is

synergistic if the effect is therapeutically superior to the effect achievable with AZD2171 or imatinib or ionising radiation alone. Further, the effect of the combination treatment is synergistic if a beneficial effect is obtained in a group of patients that does not respond (or responds poorly) to AZD2171 or imatinib or ionising radiation alone. In addition, the effect of the combination treatment is defined as affording a synergistic effect if one of the components is dosed at its conventional dose and the other component(s) is/are dosed at a reduced dose and the therapeutic effect, as measured by, for example, the extent of the response, the response rate, the time to disease progression or the survival period, is equivalent to that achievable on dosing conventional amounts of the components of the combination treatment. In particular, synergy is deemed to be present if the conventional dose of AZD2171 or imatinib or ionising radiation may be reduced without detriment to one or more of the extent of the response, the response rate, the time to disease progression and survival data, in particular without detriment to the duration of the response, but with fewer and/or less troublesome side-effects than those that occur when conventional doses of each component are used.

As stated above the combination treatments of the present invention as defined herein are of interest for their antiangiogenic and/or vascular permeability effects. Angiogenesis and/or an increase in vascular permeability is present in a wide range of disease states including cancer (including leukaemia, multiple myeloma and lymphoma), diabetes, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, arterial restenosis, autoimmune diseases, acute inflammation, lymphoedema, endometriosis, dysfunctional uterine bleeding and ocular diseases with retinal vessel proliferation including age-related macular degeneration. Combination treatments of the present invention are expected to be particularly useful in the prophylaxis and treatment of diseases such as cancer and Kaposi's sarcoma. In particular such combination treatments of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the colon, pancreas, brain, bladder, breast, prostate, lungs and skin. Combination treatments of the present invention are expected to slow advantageously the growth of tumours in colorectal cancer and in lung cancer, for example mesothelioma, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). More particularly such combination treatments of the invention are expected to inhibit any form of cancer associated with

VEGF including leukaemia, multiple myeloma and lymphoma and also, for example, to inhibit the growth of those primary and recurrent solid tumours which are associated with VEGF, especially those tumours which are significantly dependent on VEGF for their growth and spread, including for example, certain tumours of the colon (including rectum),  
5 pancreas, brain, bladder, breast, prostate, lung, vulva, skin and particularly NSCLC. More especially combination treatments of the present invention are expected to slow advantageously the growth of gastrointestinal stromal tumours (GIST). More especially combination treatments of the present invention are expected to slow advantageously the growth of tumours in small cell lung cancer (SCLC). More especially combination  
10 treatments of the present invention are expected to slow advantageously the growth of hepatocellular carcinoma (HCC). More especially combination treatments of the present invention are expected to slow advantageously the growth of soft tissue sarcomas such as leiomyosarcoma. More especially combination treatments of the present invention are expected to inhibit leukaemias particularly chronic myelogenous leukaemia (CML). In  
15 particular combination treatments of the present invention are expected to inhibit myeloproliferative disorders and myelodysplastic syndrome. In particular combination treatments of the present invention are expected to slow advantageously the growth of tumours of the brain such as malignant glioma and glioblastoma multiforme (GBM).

In another aspect of the present invention AZD2171 and imatinib, optionally with  
20 ionising radiation, are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with VEGF especially those tumours which are significantly dependent on VEGF for their growth and spread.

The compositions described herein may be in a form suitable for oral administration, for example as a tablet or capsule, for nasal administration or  
25 administration by inhalation, for example as a powder or solution, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) for example as a sterile solution, suspension or emulsion, for topical administration for example as an ointment or cream, for rectal administration for example as a suppository or the route of administration may be by direct injection into the tumour or by regional delivery or by  
30 local delivery. In other embodiments of the present invention the AZD2171 of the combination treatment may be delivered endoscopically, intratracheally, intralesionally, percutaneously, intravenously, subcutaneously, intraperitoneally or intratumourally.

Preferably AZD2171 is administered orally. In general the compositions described herein may be prepared in a conventional manner using conventional excipients. The compositions of the present invention are advantageously presented in unit dosage form.

AZD2171 will normally be administered to a warm-blooded animal at a unit dose  
5 within the range 1-50mg per square metre body area of the animal, for example  
approximately 0.03-1.5 mg/kg in a human. A unit dose in the range, for example, 0.01-  
1.5mg/kg, preferably 0.03-0.5mg/kg is envisaged and this is normally a  
therapeutically-effective dose. A unit dosage form such as a tablet or capsule will usually  
contain, for example 1-50mg of active ingredient. Preferably a daily dose in the range of  
10 0.03-0.5mg/kg is employed.

Imatinib may be dosed according to known routes of administration and dosages.

For example imatinib may be dosed at 400mg/day for patients in chronic phase  
CML.

For example imatinib may be dosed at 400-800mg/day for patients in accelerated  
15 phase CML.

For example imatinib may be dosed at 600mg/day for patients in blast crisis CML.

For example imatinib may be dosed at 400mg-600mg/day for patients with GIST.

The dosages and schedules may vary according to the particular disease state and  
the overall condition of the patient. Dosages and schedules may also vary if, in addition to  
20 a combination treatment of the present invention, one or more additional chemotherapeutic  
agents is/are used. Scheduling can be determined by the practitioner who is treating any  
particular patient.

Radiotherapy may be administered according to the known practices in clinical  
radiotherapy. The dosages of ionising radiation will be those known for use in clinical  
25 radiotherapy. The radiation therapy used will include for example the use of  $\gamma$ -rays, X-  
rays, and/or the directed delivery of radiation from radioisotopes. Other forms of DNA  
damaging factors are also included in the present invention such as microwaves and UV-  
irradiation. For example X-rays may be dosed in daily doses of 1.8-2.0Gy, 5 days a week  
for 5-6 weeks. Normally a total fractionated dose will lie in the range 45-60Gy. Single  
30 larger doses, for example 5-10Gy may be administered as part of a course of radiotherapy.  
Single doses may be administered intraoperatively. Hyperfractionated radiotherapy may  
be used whereby small doses of X-rays are administered regularly over a period of time,

for example 0.1Gy per hour over a number of days. Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and on the uptake by cells.

The size of the dose of each therapy which is required for the therapeutic or prophylactic treatment of a particular disease state will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient. For example, it may be necessary or desirable to reduce the above-mentioned doses of the components of the combination treatments in order to reduce toxicity.

The present invention relates to combinations of imatinib with AZD2171 or with a salt of AZD2171.

Salts of AZD2171 for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of AZD2171 and its pharmaceutically acceptable salts. Pharmaceutically acceptable salts may, for example, include acid addition salts. Such acid addition salts include for example salts with inorganic or organic acids affording pharmaceutically acceptable anions such as with hydrogen halides or with sulphuric or phosphoric acid, or with trifluoroacetic, citric or maleic acid. In addition pharmaceutically acceptable salts may be formed with an inorganic or organic base which affords a pharmaceutically acceptable cation. Such salts with inorganic or organic bases include for example an alkali metal salt, such as a sodium or potassium salt and an alkaline earth metal salt such as a calcium or magnesium salt.

AZD2171 may be synthesised according to the processes described in WO 00/47212, in particular those described in Example 240 of WO 00/47212.

Imatinib is commercially available.

For example, the following test may be used to demonstrate the activity of AZD2171 in combination with imatinib.

#### C6 Rat Glial Xenograft model

Tumour implantation procedures were performed on mice of at least 8 weeks of age. Rat tumour xenografts were grown in female athymic (nu/nu genotype, Swiss) mice. C6 Rat glial cells ( $1 \times 10^4$  per mouse) were injected subcutaneously (s.c.) in the right flanks of the experimental athymic mice. Ten days after cellular implant, tumours were

established and mice randomised into groups (10 animals/group) before treatment was started. AZD2171 and imatinib were each suspended in a 1% (v/v) aqueous solution of polyoxyethylene (20) sorbitan mono-oleate and administered by once daily oral gavage. When AZD2171 and imatinib were given in combination they were co-formulated in a single solution before being administered. Solutions were dosed at a volume of 10ml/kg  
5 body weight. Animals were treated with either imatinib (150mg/kg/day) alone, AZD2171 (3mg/kg/day) alone, or imatinib (150mg/kg/day) and AZD2171 (3mg/kg/day) for the duration of the study.

Tumour volumes were assessed from the start of treatment by bilateral Vernier  
10 caliper measurement. Growth inhibition from the start of treatment was assessed by comparison of the differences in tumour volume between control and treated groups.

Statistical significance was evaluated using a one-tailed t-test.

The data is shown in Figure 1. The growth inhibition of tumours was significantly  
15 greater with the combination of the two agents, AZD2171 and imatinib, than with either agent alone.


An analogous experiment may be used to look at the combination of AZD2171 and imatinib with ionising radiation.

CLAIMS

1. Use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of a medicament for use in the production of an antiangiogenic and/or  
5 vascular permeability reducing effect in a warm-blooded animal such as a human.
2. Use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of a medicament for use in the production of an anti-cancer effect in a  
warm-blooded animal such as a human.  
10
3. Use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of a medicament for use in the production of an anti-tumour effect in a  
warm-blooded animal such as a human.
- 15 4. Use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
- 20 5. Use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of a medicament for use in the production of an anti-cancer effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
- 25 6. Use of AZD2171 or a pharmaceutically acceptable salt thereof and imatinib in the manufacture of a medicament for use in the production of an anti-tumour effect in a warm-blooded animal such as a human which is being treated with ionising radiation.
7. Use according to claim 3 or claim 6 wherein the tumour is a gastrointestinal stromal tumour (GIST).  
30
8. Use according to claim 2 or claim 5 wherein the cancer is small cell lung cancer (SCLC).

9. Use according to claim 2 or claim 5 wherein the cancer is a leukaemia.
10. Use according to claim 9 wherein the leukaemia is chronic myelogenous leukaemia  
5 (CML).
11. A pharmaceutical composition which comprises AZD2171 or a pharmaceutically acceptable salt thereof, and imatinib in association with a pharmaceutically acceptable excipient or carrier.  
10
12. A kit comprising AZD2171 or a pharmaceutically acceptable salt thereof and imatinib.
13. A method for the production of an antiangiogenic and/or vascular permeability  
15 reducing effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib.
- 20 14. A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human, which comprises administering to said animal an effective amount of AZD2171 or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of imatinib and before, after or simultaneously with an effective amount of ionising radiation.  
25

1 of 1



Imatinib 150mg/kg/d vs Imatinib 150mg/kg/d + AZD2171 3mg/kg/d      p<0.001

AZD2171 3mg/kg/d vs Imatinib 150mg/kg/d + AZD2171 3mg/kg/d      p<0.001

**Figure 1**

INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB2005/003672

A. CLASSIFICATION OF SUBJECT MATTER  
A61K31/506 A61K31/517 A61P35/00 A61P35/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)  
EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data, CANCERLIT, SCISEARCH, PASCAL

C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00/47212 A (ASTRAZENECA UK LIMITED; ZENECA-PHARMA S.A; HENNEQUIN, LAURENT, FRANCOI) 17 August 2000 (2000-08-17) cited in the application page 2, line 15 - line 17 page 84, line 30 - page 86, line 10 example 240	1-14
Y	GB 2 398 565 A (* CIPLA LIMITED) 25 August 2004 (2004-08-25) page 16, paragraph 3	1-6,8, 11-14

Further documents are listed in the continuation of box C.  Patent family members are listed in annex.

° Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed
- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search <b>24 November 2005</b>	Date of mailing of the international search report <b>06/12/2005</b>
--	---

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer <b>Albrecht, S</b>
--	--

## INTERNATIONAL SEARCH REPORT

 International Application No  
 PCT/GB2005/003672

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DUDLEY A ET AL: "STI-571 inhibits in vitro angiogenesis" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 310, no. 1, 10 October 2003 (2003-10-10), pages 135-142, XP004457195 ISSN: 0006-291X the whole document	1-7,9-14
Y	DEMETRI GEORGE D ET AL: "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors" NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, BOSTON, MA, US, vol. 347, no. 7, 15 August 2002 (2002-08-15), pages 472-480, XP002307009 ISSN: 1533-4406 the whole document	1-7,9-14
Y	O'DWYER M E ET AL: "STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia" LANCET ONCOLOGY, LANCET PUBLISHING GROUP, LONDON, GB, vol. 1, no. 4, December 2000 (2000-12), pages 207-211, XP004813948 ISSN: 1470-2045 the whole document	1-6,9-14

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB2005/003672

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 13, 14  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 13, 14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intel	ional Application No
PCT/GB2005/003672	

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0047212	A	17-08-2000	AT 298237 T 15-07-2005
			AU 763618 B2 31-07-2003
			AU 2447500 A 29-08-2000
			BR 0008128 A 13-02-2002
			CA 2362715 A1 17-08-2000
			CN 1346271 A 24-04-2002
			CN 1597667 A 23-03-2005
			CZ 20012889 A3 14-11-2001
			DE 60020941 D1 28-07-2005
			EE 200100409 A 16-12-2002
			HU 0104964 A2 29-04-2002
			ID 30552 A 20-12-2001
			JP 2002536414 T 29-10-2002
			MX PA01008182 A 20-08-2003
			NO 20013882 A 09-10-2001
			NZ 513204 A 30-04-2004
			NZ 530832 A 27-05-2005
			PL 350565 A1 16-12-2002
			SK 11402001 A3 07-01-2002
			TR 200102314 T2 21-01-2002
TR 200500745 T2 23-05-2005			
ZA 200106340 A 01-11-2002			
GB 2398565	A	25-08-2004	AU 2004213616 A1 02-09-2004
			CA 2516370 A1 02-09-2004
			WO 2004074502 A2 02-09-2004